Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Endocrinology · Immunotherapy-Induced Hypophysitis

Standard of Care Treatment and Hormone Replacement

At a Glance

Immunotherapy-induced hypophysitis is usually managed by replacing missing cortisol and, when needed, thyroid hormone, with cortisol addressed first. Adrenal crisis requires immediate hydrocortisone and fluids; high-dose steroids are reserved for pressure on the optic nerves or severe swelling.

Managing immunotherapy-induced hypophysitis (IIH) requires a shift in how you think about steroids. Unlike many other immune-related side effects where high doses of steroids are used to “shut down” the inflammation, IIH treatment is primarily about hormone replacement—replacing exactly what your body normally makes but is currently lacking [1][2].

Emergency Care: Adrenal Crisis

If you show signs of an adrenal crisis—such as severe vomiting, confusion, or a dangerous drop in blood pressure—treatment must be immediate. This is a medical emergency where every minute counts [3][4].

  • Immediate Action: You should receive a high-dose “bolus” of hydrocortisone through an IV or as an injection into the muscle [5][6].
  • Fluid Support: Doctors will also provide IV fluids (saline) to stabilize your blood pressure and correct electrolyte imbalances like low sodium [7][8].
  • No Delays: Medical guidelines are clear: if a crisis is suspected, doctors should give the steroids first. They should not wait for an MRI or the results of a blood test to confirm the diagnosis [4][9].

Long-Term Hormone Replacement

Once you are stable, the goal is to provide a “physiologic” dose of hormones. This means giving you a dose that mimics the natural levels your pituitary gland would normally signal your body to produce [10][11].

The Adrenal Axis (The Most Critical)

You will likely be prescribed hydrocortisone or prednisone. Hydrocortisone is often preferred because it is short-acting and can be split into two or three doses (for example, 10 mg in the morning and 5 mg in the afternoon) to mimic the body’s natural daily rhythm [10][12].

  • A Long-Term Commitment: Recovery of the ACTH (cortisol) axis is uncommon. Most patients require long-term, daily steroid replacement [13][14]. Because adrenal function rarely recovers, you must never stop taking your glucocorticoids independently, even if you feel well. Only a specialist should manage reassessment or dose reductions [13][15].

The Thyroid Axis: The “Rule of Order”

If your pituitary gland is also failing to signal your thyroid (central hypothyroidism), you will need levothyroxine, which is monitored by checking your Free T4 levels rather than just TSH [16].

There is a crucial safety rule: your doctor must assess and treat potential cortisol deficiency before starting levothyroxine [17].

  • The Risk: Thyroid hormone speeds up your metabolism and increases how quickly your body clears cortisol. If you start levothyroxine while your cortisol is still untreated and low, the increased demand and rapid clearance of cortisol can inadvertently precipitate a life-threatening adrenal crisis [17].

The Role of High-Dose Steroids

You may hear about other patients receiving very high “immunosuppressive” doses of steroids (like 1mg/kg of prednisone). In the context of IIH, these high doses are generally not recommended for routine treatment [10][1].

  • Why Avoid High Doses? Research shows that high-dose steroids do not help the pituitary gland recover its function [18][14]. Furthermore, high doses can cause side effects like high blood sugar, weight gain, and even psychiatric issues like psychosis [10][15].
  • When High Doses Are Used: Doctors reserve high-dose steroids only for “mass effect” situations—when the pituitary gland is so swollen that it is pressing on the optic nerves (threatening your vision or causing double vision) or causing a severe, rapidly worsening headache [1][2][19].

Continuing Your Cancer Treatment

The good news is that a diagnosis of hypophysitis does not usually mean you have to stop your immunotherapy forever. Most patients can restart or continue their cancer treatment once their hormone replacement levels are stabilized and they feel well [1][2][20]. Your oncology and endocrinology teams will work together to monitor your levels and ensure you are safe to proceed [21][22].

Common questions in this guide

What is the usual treatment for hypophysitis caused by immunotherapy?
The main treatment is replacement of hormones that the pituitary is no longer signaling the body to make. Hydrocortisone or prednisone is used for low cortisol, and levothyroxine may be used for low thyroid function after cortisol deficiency has been assessed. High-dose steroids are not routinely needed unless pituitary swelling is pressing on the optic nerves or causing severe, rapidly worsening symptoms.
What should I do if I may be having an adrenal crisis?
Severe vomiting, confusion, or a dangerous fall in blood pressure requires emergency medical care. Treatment should begin with high-dose hydrocortisone through a vein or into a muscle and IV saline; clinicians should not delay steroids while waiting for blood tests or an MRI.
Why does cortisol treatment come before thyroid medicine?
If the pituitary is not stimulating the adrenal glands, cortisol can be dangerously low. Starting levothyroxine first can increase the body’s demand for cortisol and speed its clearance, which may trigger a life-threatening adrenal crisis.
Will I need steroid replacement for a long time after hypophysitis?
Most people with immunotherapy-induced hypophysitis need daily glucocorticoid replacement because recovery of the pituitary signal that controls cortisol is uncommon. Do not stop or reduce hydrocortisone or prednisone on your own; an endocrinologist should decide when and how to reassess it.
When are high-dose steroids used for immunotherapy-induced hypophysitis?
Routine high-dose immunosuppressive steroids generally do not restore pituitary function and can cause problems such as high blood sugar, weight gain, and psychiatric effects. Doctors may use them when swollen pituitary tissue is pressing on the optic nerves or causing vision changes, double vision, or a severe, rapidly worsening headache; an adrenal crisis also requires immediate high-dose hydrocortisone.
Can cancer immunotherapy be restarted after hypophysitis?
Often, yes. Once hormone replacement is stable and you feel well, your oncology and endocrinology teams can decide whether and when to resume treatment and how to monitor you.
How should I prepare for illness while taking hormone replacement?
Ask for a written sick-day plan that explains when to increase your steroid dose, and learn how to use an emergency injection if one is prescribed. Make sure a caregiver or family member knows the plan and where your emergency kit is kept.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my exact maintenance dose for hydrocortisone, and how should I split it throughout the day?
  2. 2.If I also have low thyroid levels, can you confirm that my steroid replacement is stable before we start the thyroid medication?
  3. 3.Since my adrenal function is unlikely to recover, how often should we re-test my other pituitary hormones to see if they might come back?
  4. 4.Under what specific circumstances would you recommend moving from a replacement dose to a 'high dose' of steroids?
  5. 5.When is it safe for me to restart my immunotherapy, and do we need to change the dosage or schedule?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management.

    Kotwal A

    Current opinion in endocrinology, diabetes, and obesity 2021; (28(4)):427-434 doi:10.1097/MED.0000000000000652.

    PMID: 34183541
  2. 2

    Hypophysitis Associated with Immune Checkpoint Inhibitors.

    Corsello A, Paragliola RM, Torino F, Salvatori R

    Endocrinology and metabolism clinics of North America 2025; (54(4)):685-702 doi:10.1016/j.ecl.2025.06.009.

    PMID: 41130657
  3. 3

    Diagnosis and Management of Adrenal Insufficiency and Adrenal Crisis in the Emergency Department.

    Lentz S, Collier KC, Willis G, Long B

    The Journal of emergency medicine 2022; (63(2)):212-220 doi:10.1016/j.jemermed.2022.06.005.

    PMID: 36038436
  4. 4

    SFE/SFEDP adrenal insufficiency French consensus: Introduction and handbook.

    Reznik Y, Barat P, Bertherat J, et al.

    Annales d'endocrinologie 2018; (79(1)):1-22 doi:10.1016/j.ando.2017.12.001.

    PMID: 29338844
  5. 5

    ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of adrenal insufficiency.

    Arlt W, Baldeweg SE, Pearce SHS, Simpson HL

    European journal of endocrinology 2020; (183(1)):G25-G32.

    PMID: 32379699
  6. 6

    [Addisonian Crisis - Risk Assessment and Appropriate Treatment].

    Meyer G, Badenhoop K

    Deutsche medizinische Wochenschrift (1946) 2018; (143(6)):392-396 doi:10.1055/s-0043-111729.

    PMID: 29544234
  7. 7

    Clinical course and management of insidious adrenal crisis manifested initially as hyperpyrexia secondary to pembrolizumab: Case reports and literature review.

    Geng D, Wang Y, Zhang X, et al.

    Frontiers in oncology 2022; (12()):981084 doi:10.3389/fonc.2022.981084.

    PMID: 36033475
  8. 8

    Late-onset hypophysitis after discontinuation of nivolumab treatment for advanced skin melanoma: a case report.

    Antoniou S, Bazazo G, Röckl L, et al.

    BMC endocrine disorders 2021; (21(1)):191 doi:10.1186/s12902-021-00854-y.

    PMID: 34544399
  9. 9

    Dexamethasone-related adrenal insufficiency in patients with brain and skull base tumours.

    Benghiat H, Sanghera P, Stange D, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2018; (26(12)):4031-4038 doi:10.1007/s00520-018-4264-4.

    PMID: 29858690
  10. 10

    High-dose glucocorticoid treatment vs. glucocorticoid replacement in immune checkpoint inhibitor associated hypophysitis (CORTICI): an open, randomised controlled trial.

    Theiler-Schwetz V, Trummer C, Schmitt L, et al.

    Annals of medicine 2025; (57(1)):2453829 doi:10.1080/07853890.2025.2453829.

    PMID: 39862267
  11. 11

    Gaps in the management of adrenal insufficiency in melanoma survivors: a retrospective cohort study.

    Lin W, Wang W, Hodi FS, Min L

    EClinicalMedicine 2025; (79()):102984 doi:10.1016/j.eclinm.2024.102984.

    PMID: 39720607
  12. 12

    Endocrinologist-Led Management of Endocrine Immune-Related Adverse Events: Real-World Evidence Supporting the Japan Endocrine Society Guidelines.

    Nishihama K, Fujimoto H, Saito K, et al.

    Cancer medicine 2026; (15(4)):e71818 doi:10.1002/cam4.71818.

    PMID: 41968610
  13. 13

    Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns.

    Nguyen H, Shah K, Waguespack SG, et al.

    Endocrine-related cancer 2021; (28(7)):419-431.

    PMID: 33890870
  14. 14

    Differences in checkpoint-inhibitor-induced hypophysitis: mono- versus combination therapy induced hypophysitis.

    van der Leij S, Suijkerbuijk KPM, van den Broek MFM, et al.

    Frontiers in endocrinology 2024; (15()):1400841 doi:10.3389/fendo.2024.1400841.

    PMID: 39135626
  15. 15

    Immune Checkpoint Inhibitor Therapy Induced Hypophysitis; A Tertiary Care Centre Experience; Highlighting Detection, Treatment Outcomes and Long Term Endocrinopathies and Recovery.

    Mathara Diddhenipothage SAD, Warden J, Herbert K, et al.

    Clinical endocrinology 2026; (105(3)):331-338 doi:10.1111/cen.70137.

    PMID: 41879139
  16. 16

    Pembrolizumab-Induced Hypophysitis: A Rare Immune-Related Adverse Event in a Patient With Metastatic Non-small Cell Lung Cancer.

    Al Heyasat A, Chaudhry MS, Alkharabsheh M, et al.

    Cureus 2025; (17(4)):e82701 doi:10.7759/cureus.82701.

    PMID: 40400852
  17. 17

    Potential pitfalls in diagnosis of immunotherapy-induced hypothalamic-pituitary-adrenal axis abnormalities: a clinical case.

    Bi Y, Adam S, Chatzimavridou V, et al.

    Endocrine oncology (Bristol, England) 2022; (2(1)):K5-K9 doi:10.1530/EO-21-0023.

    PMID: 37435468
  18. 18

    Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.

    Thapi S, Leiter A, Galsky M, Gallagher EJ

    Journal for immunotherapy of cancer 2019; (7(1)):248 doi:10.1186/s40425-019-0729-3.

    PMID: 31511065
  19. 19

    [Autoimmune hypophysitis associated with new anti-cancer immunotherapies].

    Jannin A, Merlen E, Do Cao C, Penel N

    Bulletin du cancer 2018; (105(3)):275-280 doi:10.1016/j.bulcan.2017.10.033.

    PMID: 29475597
  20. 20

    Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline.

    Husebye ES, Castinetti F, Criseno S, et al.

    European journal of endocrinology 2022; (187(6)):G1-G21 doi:10.1530/EJE-22-0689.

    PMID: 36149449
  21. 21

    Pituitary and adrenal disorders induced by immune checkpoint inhibitors.

    Albarel F, Brue T, Castinetti F

    Annales d'endocrinologie 2023; (84(3)):339-345 doi:10.1016/j.ando.2023.03.014.

    PMID: 36965852
  22. 22

    MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis.

    Albarel F, Castinetti F, Brue T

    European journal of endocrinology 2019; (181(3)):R107-R118.

    PMID: 31311002

This page is for informational purposes only and does not constitute medical advice about immunotherapy-induced hypophysitis. Do not change steroid or thyroid medicines without guidance from your oncology or endocrinology team.

Get notified when new evidence is published on Immunotherapy induced hypophysitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.